Federal grants to Cartesian Therapeutics Inc
Cartesian Therapeutics Inc in Frederick, Maryland received $7.3 million in federal grants from fiscal 2021 to 2025, across 5 awards. Its largest program was Extramural Research Programs in the Neurosciences and Neurological Disorders, with $4.1 million. In fiscal 2025 it was awarded $1.5 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$7.3 million
- Awards5
- Awarded in FY 2025$1.5 million
- Largest award$3.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 3 | $3.1 million |
| FY 2022 | 1 | $999,491 |
| FY 2023 | 0 | $0 |
| FY 2024 | 2 | $1.6 million |
| FY 2025 | 1 | $1.5 million |
Programs that fund Cartesian Therapeutics Inc
| Program | Awards | Amount |
|---|---|---|
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 2 | $4.1 million |
| Cardiovascular Diseases Research | 1 | $2.0 million |
| Cancer Treatment Research | 1 | $988,226 |
| Trans-NIH Research Support | 1 | $149,008 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 5 | $7.3 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Manufacturing rna-based car t cells to combat autoantibody-associated autoimmune disorders (AAAD) - autoantibody-associated autoimmune diseases (AAADS) are disorders in which dysfunctional plasma cells (PCS) secrete autoantibodies that attack healthy tissue. Many aaads attack the nervous system, suc | Extramural Research Programs in the Neurosciences and Neurological Disorders | June 7, 2024 | $3.0 million |
| Phase 1/2A clinical study of DESCARTES-30 in acute respiratory distress syndrome - abstract this application is to support a clinical trial of the first mrna engineered cell therapy for acute respiratory distress syndrome (ARDS), including ards caused by COVID-19. The fda has already reviewed the in | Cardiovascular Diseases Research | April 29, 2021 | $2.0 million |
| Autologous t-cells expressing a chimeric antigen receptor directed to b-cell maturation antigen (BCMA) in patients with generalized myasthenia gravis (MG) | Extramural Research Programs in the Neurosciences and Neurological Disorders | June 24, 2021 | $1.2 million |
| Phase 1/2 clinical study of humanized anti-bcma car t cells in relapsed/refractory multiple myeloma (MM) | Cancer Treatment Research | April 3, 2021 | $988,226 |
| Targeting bcma+ cells with rna-engineered car t cells to treat lupus: a phase 2 clinical study - systemic lupus erythematosus (SLE) is an autoimmune disease that impacts over 3 million people, causing joint pain, organ damage, and impaired quality of life. Existing sle drugs are non-specific and cau | Trans-NIH Research Support | August 14, 2024 | $149,008 |
Questions people ask
How much federal grant money does Cartesian Therapeutics Inc get?
$7.3 million in 5 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Cartesian Therapeutics Inc the most?
The Department of Health and Human Services, with $7.3 million in 5 awards.
What is Cartesian Therapeutics Inc's largest federal grant?
$3.0 million under Extramural Research Programs in the Neurosciences and Neurological Disorders, with its first action in the period on June 7, 2024. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Cartesian Therapeutics Inc?
Its largest are Extramural Research Programs in the Neurosciences and Neurological Disorders, Cardiovascular Diseases Research and Cancer Treatment Research.
Other grant recipients in Frederick
- City of Frederick
- Frederick County Maryland
- The Young Men's Christian Association of Frederick County, Maryland, Incorporated
- Housing Authority of the City of Frederick Corporation
- Frederick Community College
- Appili Therapeutics USA Inc.
- Hood College of Frederick, Maryland
- Theradaptive Inc
Largest federal grant recipients in Maryland · Federal grants in Maryland